SALL4 Peptide Inhibitor for Solid Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective targets for certain subtypes of solid tumors, particularly those expressing SALL4, where existing molecules are difficult to target or not druggable, and there is a need for improved treatments for cancers like liver, endometrial, and ovarian tumors.
Innovation Solution
Identification of SALL4 as a molecular target for targeted cancer therapy using short hairpin ribonucleic acid (shRNA) and a 12-amino acid peptide to inhibit SALL4 expression in SALL4-expressing tumors, disrupting its interaction with the NuRD complex and releasing the transcriptional repression of PTEN, thereby inhibiting tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cancer therapy molecules are used, then treatment is provided, but the molecules are difficult to target or not druggable for solid tumors expressing SALL4
Solution Approach 1:
The patent extracts the critical interaction interface between SALL4 and NuRD complex by identifying the 12-amino acid peptide sequence (MSRRKQAKPQHI) that mediates this interaction. By isolating this specific functional region, the invention creates a targeted therapeutic approach that disrupts the SALL4-NuRD interaction without requiring modification of the entire complex system, thereby making previously undruggable SALL4 expressable tumors targetable.
Solution Approach 2:
The patent introduces a peptide-based intermediary agent that competitively binds to the SALL4-NuRD interaction interface. This peptide acts as a mediator that blocks the direct interaction between SALL4 and NuRD complex, preventing transcriptional repression of PTEN and thereby inhibiting tumor cell proliferation. The intermediary peptide provides a druggable target for solid tumors expressing SALL4.
2Productivity
If SALL4 is targeted using shRNA or peptide, then tumor cell viability is reduced, but the mechanism is complex and requires specific delivery systems
Solution Approach 1:
The patent changes the therapeutic parameter from genetic manipulation (shRNA) to protein interaction disruption (peptide). By using a small molecule peptide that directly binds to and disrupts the SALL4-NuRD interaction, the invention simplifies the delivery mechanism compared to viral vectors required for shRNA. The peptide can be administered via conventional routes and rapidly disrupts the harmful interaction without requiring complex genetic modification or viral delivery systems.
3Productivity
If SALL4 expression is inhibited, then tumor growth is inhibited, but specificity must be maintained to avoid affecting normal tissues
Solution Approach 1:
The patent applies local quality by targeting a specific interaction interface (the 12-amino acid peptide sequence) that is uniquely involved in SALL4-NuRD binding. This localized targeting approach disrupts the interaction specifically at the molecular interface level, preventing PTEN repression in tumor cells while leaving other normal functions of SALL4 in non-tumor tissues unaffected. The specificity is achieved through precise molecular recognition rather than broad gene silencing.
Data Source
AI summary
Described are methods of treating a solid tumor which expresses Spalt-Like Transcription Factor 4 (SALL4) and Phosphatase and Tensin Homolog (PTEN) in an individual in need thereof, comprising administering to the individual an effective amount of a composition that inhibits SALL4. In addition, the invention is directed to methods of detecting an aggressive cancer in an individual in need thereof as well as methods of detecting a poor prognosis of a patient with cancer in an individual in need thereof.